StockWatch
·

SEQUENT SCIENTIFIC LTD. Q2 FY27 Results

VIYASHQ2 FY27 Results
Filing
Result:Good· Market: Crashed#Margin squeeze#Record quarter
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue987.944.4%133.0%
Total Income999.724.7%134.6%
Expenditure882.044.7%122.0%
PBT117.684.7%333.3%
Net Profit84.656.8%331.9%
OPM16.70%2.15pp3.97pp
NPM8.47%0.16pp3.87pp
EPS1.7415.2%194.9%
View full financials

Adjusted (like-for-like) PAT and revenue grew ~16% YoY, modestly ahead of management's 13-15% API guidance, but operating margin compression (16.7% vs restated 20.37% a year ago) on rising material and ESOP-driven employee costs caps this below very_good.

Q2 FY-2027 RESULTS · VIYASH

Viyash Q2 FY27: Consolidated PAT ₹84.7 Cr, ~16% Like-for-Like Growth as Margins Compress

PAT +331.89% YoY · revenue +133.01% · margins compressing

13 Nov 2026 · 3 min read
Revenue

₹987.94 Cr

+133.01% YoY

PAT (consolidated)

₹84.65 Cr

+331.89% YoY

Net margin

8.47%

+3.9pp YoY

EPS

₹1.74

Viyash Scientific (formerly Sequent Scientific) posted consolidated revenue of ₹987.94 Cr and PAT of ₹84.65 Cr for Q2 FY27, up 4.4% and 6.8% sequentially over Q1 FY27's ₹946.36 Cr/₹79.29 Cr. The headline YoY jump against our database's year-ago base (₹423.99 Cr revenue, ₹19.60 Cr PAT) looks explosive at +133%/+332%, but that comparison predates the Composite Scheme of Amalgamation that folded SeQuent Research, Viyash Life Sciences and several other group entities into the listed company under pooling-of-interest accounting. The filing's own restated year-ago column — ₹850.30 Cr revenue, ₹72.90 Cr PAT — is the real like-for-like base, putting organic YoY growth at a much steadier ~16.2% on revenue and ~16.1% on PAT (adjusted). That is roughly in line with, or modestly ahead of, management's FY27 guidance of 13-15% API segment growth, though this is a total-company read rather than segment-specific.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹987.94 Cr+4.4%+133%
Expenses₹882.04 Cr+4.7%+122%
PAT₹84.65 Cr+6.76%+331.89%
Net margin8.47%+0.2pp+3.9pp
EPS₹1.74+15.2%+194.9%

Margins moved the other way: operating margin (EBITDA/revenue, ex-other income) slipped to 16.7% from 18.85% in Q1 FY27 and from a restated 20.37% a year ago, even as net profit margin held roughly flat at 8.47% (vs 8.31% QoQ, 8.50% restated YoY) — tax and finance-cost ratios offset most of the operating squeeze. The compression traces mainly to cost of materials rising to 44.4% of revenue from 42.5% in Q1 FY27, plus a step-up in employee costs to 18.7% of revenue from 17.2%; part of that increase is the non-cash ESOP charge of ₹37.7 Cr this quarter (₹56.3 Cr for H1) under the new Scheme 2026 ESOP, following the February 2026 grant of 1.31 crore options.

₹
195.28218.27241.27264.26287.25255.3208-1009-0109-2410-1911-1111-13Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹255.32, up 9.6% over the past month of trading.

₹ Cr
031.663.2194.8117.57Q1 FY26rev ₹441 Cr19.6Q2 FY26rev ₹424 Cr48.52Q3 FY26rev ₹858 Cr66.38Q4 FY26rev ₹920 Cr79.29Q1 FY27rev ₹946 Cr84.65Q2 FY27rev ₹988 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.

Beyond the headline

What the summary numbers don't show

Consolidated basic EPS ₹1.74 vs ₹1.51 in Q1 FY27

What management guided (1 FY-2027 call)
FY27 overall API growth 13–15% double-digit; companion animal formulation targeting 20%+ expansion; EV acquisition (BioForLife Italy) to close next few months, 18–24 month registration cycle. ₹250–300 Cr capex this year. 1 billion revenue target by FY32 at 18% CAGR.

— This quarter: met

No street preview or consensus estimate specific to this quarter turned up in search — full-year FY27 consensus (revenue ~₹3,900 Cr, +14%) exists on aggregator sites but nothing quarter-specific, so vs-street is marked unknown rather than guessed. Management's own press release was not available in the context to cross-check framing. The quarter's corporate actions tie into the guided EV/companion-animal push: the BioForLife Italia S.r.l. acquisition (flagged in the prior concall as pending) completed on October 1, 2026 for the full equity stake, and the company incorporated a new Vietnam subsidiary on November 2, 2026, both consistent with the stated geographic and portfolio expansion plan. A Senior VP-HR change and a 2% stake sale by White Oak Capital occurred in the quarter but carry no direct read-through to the P&L.

  • W1

    Whether operating margin recovers toward the 19-20% range seen in Q1 FY27 and the restated year-ago quarter, or the 16-17% level persists as the post-merger/post-ESOP baseline

  • W2

    Like-for-like growth trajectory against management's guided FY27 API growth of 13-15% and companion-animal formulation growth of 20%+, tracked off the ~16% H1 like-for-like base

  • W3

    Integration contribution and costs from BioForLife Italia (completed Oct 1, 2026) and the new Vietnam subsidiary in upcoming quarters

Clean digital filing, column headers unambiguous, arithmetic ties exactly on both statements. Consolidated PAT of ₹84.65 Cr includes NCI of ₹8.48 Cr (owners' PAT ₹76.17 Cr). No exceptional items this quarter vs a ₹1.70 Cr amalgamation-related exceptional loss in the restated year-ago quarter. Reported YoY comps vs our DB base (pre-merger ₹423.99 Cr revenue/₹19.60 Cr PAT) are inflated by the Scheme of Amalgamation (pooling-of-interest restatement effective 16-Dec-2025); the filing's own restated year-ago column (₹850.30 Cr revenue/₹72.90 Cr PAT) is the true like-for-like base.

Informational and educational content only. Not investment advice.